Davendra Mehta, MD
Clinical Cardiac Electrophysiology · Richmond Hill, NYNPI 1326084971
Payments from drug & device makers
What this record shows
This record is dominated by grants: $25,000 of the $37,636 with a category attached, or 66.4%. Medtronic accounts for 68.6% of it on its own, with 24 other manufacturers making up the rest. Reporting peaked in 2020 at $25,179 and has fallen 89.5% since, to $2,642 in 2025.
Across 155 payments — averaging $242.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$26K
- Boston Scientific$5K
- Abbott$4K
- Stereotaxis Inc$738
- Biosense Webster, Inc.$599
- E.r. Squibb & Sons, L.L.C.$223
- plus $1K from 19 others
Across 43 payments — averaging $122.08 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biotronik Inc.$5K
What the payments were for
- Consulting fees$9503%
- Grants$25,00066%
- Travel & lodging$5,60915%
- Food & beverage$6,07616%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 16 | $25,831 |
| Boston Scientific | 26 | $4,797 |
| Abbott | 55 | $4,428 |
| Stereotaxis Inc | 2 | $738 |
| Biosense Webster, Inc. | 11 | $599 |
| E.r. Squibb & Sons, L.L.C. | 10 | $223 |
| Philips North America LLC | 2 | $126 |
| Cardiva Medical, Inc. | 3 | $103 |
| Pfizer | 5 | $103 |
| Johnson & Johnson | 4 | $79 |
| Scpharmaceuticals Inc. | 2 | $73 |
| Amgen | 3 | $68 |
| Bayer | 2 | $62 |
| Alnylam Pharmaceuticals Inc. | 2 | $57 |
| Baylis Medical Company Inc | 1 | $47 |
| Cordis US CORP. | 2 | $41 |
| Kestra Medical Technology Services, Inc. | 1 | $40 |
| Impulse Dynamics (USA) Inc. | 1 | $37 |
| Boehringer Ingelheim | 1 | $34 |
| Angiodynamics, Inc. | 1 | $29 |
| Lantheus Medical Imaging, Inc. | 1 | $28 |
| Alcresta Therapeutics, Inc. | 1 | $26 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $22 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $22 |
| AstraZeneca | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AVEIR$1,969
- INGEVITY$1,177
- Accent Pacemaker$950
- Niobe$655
- Carto 3$337
- LINQ II$246
- Farapulse$244
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$140
- HeartMate 3 Left Ventricular Dev$129
- GENERAL - THERAPIES$127
- Mitra Clip system$125
- Ensite Cardiac Mapping System$124
- Carto 3 System$113
- GlideLight$105
How this compares
$37,636 in reported general payments places this provider in the 65th percentile of 214 clinical cardiac electrophysiology providers in New York.
See all clinical cardiac electrophysiology providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 236 | $207,859 |
| XareltoRivaroxaban | 21 | $31,322 |
| Metoprolol Succinate | 153 | $2,692 |
| Amiodarone Hcl | 36 | $781 |
| Flecainide Acetate | 11 | $512 |
| Metoprolol Tartrate | 18 | $154 |
| Carvedilol | 11 | $116 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $103 | $207,859236 claims |
| Johnson & JohnsonXarelto | $79 | $31,32221 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 214 clinical cardiac electrophysiology providers in New York.
Other clinical cardiac electrophysiology in Richmond Hill
- Vivek ReddyNew York$14.9M
- Jacob KoruthNew York$3.7M
- Srinivas DukkipatiNew York$2.7M
- Amir AhmadiNew York$789K
- Larry ChinitzNew York$448K
- Felix YangBrooklyn$407K
- James IpNew York$347K
- Stavros MountantonakisManhasset$321K
- Jorge RomeroSyracuse$295K
- Nicholas SkipitarisNew York$293K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.